THE CHOICE BETWEEN SPLENECTOMY AND MEDICAL-TREATMENT IN PATIENTS WITH ADVANCED AGNOGENIC MYELOID METAPLASIA

The objective of the study was to explore the risks and benefits of splenectomy in advanced agnogenic myelod metaplasia (AMM). We searched the literature (Medline, 1970‐1987) for studies of postoperative survival, operative mortality and effects of splenectomy on painful splenomegaly, and portal hypertension or transfusion requirements in patients with AMM. We employed formal decision analysis to determine the relative value of medical and surgical treatment of advanced AMM. Results of data synthesis showed that splenectomy in AMM is associated with an operative mortality of 13.4% (95% confidence intervals (Cl): 9.5‐1 ‐17.2%), an early morbidity of 45.3% (Cl: 39.6‐51.1%), and a late morbidity of 16.3% (Cl: 9.9‐22.5%). Almost all patients with portal hypertension and painful splenomegaly, but only about half of those with thrombopenia and anemia were reported to have experienced relief in their symptoms or signs after splenectomy. We found no evidence that splenectomy affects survival in AMM. We concluded that splenectomy in advanced AMM is a palliative procedure that carries a substantial risk. It may be considered for symptomatic patients after they have been informed about the operative mortality, morbidity, and chances of palliation. Decisions about treatment of advanced AMM should be guided predominantly by the patient's preferences. Copyright © 1990 Wiley‐Liss, Inc., A Wiley Company